Cited 4 times in
Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박중원 | - |
dc.date.accessioned | 2022-09-14T01:27:11Z | - |
dc.date.available | 2022-09-14T01:27:11Z | - |
dc.date.issued | 2021-07 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190453 | - |
dc.description.abstract | Background/aims: Omalizumab is the first biologic known to be effective in patients with severe allergic asthma. Methods: This study was conducted as a multicenter, single-group, open trial to evaluate the improvement in the quality of life with the additional administration of omalizumab for 24 weeks in Korean patients with severe persistent allergic asthma. Results: Of the 44 patients, 31.8% were men and the mean age was 49.8 ± 11.8 years. A score improvement of 0.5 points or more in the Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) was noted in 50.0% (22/44) of the patinets. In the improved group, the baseline total immunoglobulin E (IgE) level and the amount of omalizumab used were higher, and the day and night asthma symptoms were more severe, compared to those in the non-improved group. According to the Global Evaluation of Treatment Effectiveness, favorable outcomes were found in 78.6% of patients. The Korean asthma control test (p < 0.005) and forced expiratory volume in 1 second % predicted (FEV1%; p < 0.01) improved significantly in patients who received omalizumab treatment, compared to that at week 0, and the total dose of rescue systemic corticosteroids significantly decreased (p < 0.05). The improved group on KAQLQ showed a significant improvement in FEV1% (p < 0.001). Conclusion: Omalizumab can be considered a biological treatment for Korean patients with severe allergic asthma. It is recommended to consider omalizumab as add-on therapy in patients with high baseline total IgE levels and severe asthma symptoms. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Association of Internal Medicine | - |
dc.relation.isPartOf | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Anti-Asthmatic Agents* / adverse effects | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized / therapeutic use | - |
dc.subject.MESH | Asthma* / diagnosis | - |
dc.subject.MESH | Asthma* / drug therapy | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Omalizumab / adverse effects | - |
dc.subject.MESH | Quality of Life | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Surveys and Questionnaires | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jae-Woo Jung | - |
dc.contributor.googleauthor | Hae-Sim Park | - |
dc.contributor.googleauthor | Choon-Sik Park | - |
dc.contributor.googleauthor | Sang-Heon Cho | - |
dc.contributor.googleauthor | Inseon S Choi | - |
dc.contributor.googleauthor | Hee-Bom Moon | - |
dc.contributor.googleauthor | Soon Seog Kwon | - |
dc.contributor.googleauthor | Ho Joo Yoon | - |
dc.contributor.googleauthor | Jung Won Park | - |
dc.contributor.googleauthor | Jong-Myung Lee | - |
dc.contributor.googleauthor | Dong-Chull Choi | - |
dc.contributor.googleauthor | Byoung Whui Choi | - |
dc.identifier.doi | 10.3904/kjim.2020.549 | - |
dc.contributor.localId | A01681 | - |
dc.relation.journalcode | J02883 | - |
dc.identifier.eissn | 2005-6648 | - |
dc.identifier.pmid | 34237826 | - |
dc.subject.keyword | Asthma | - |
dc.subject.keyword | Omalizumab | - |
dc.subject.keyword | Prospective studies | - |
dc.subject.keyword | Quality of life | - |
dc.subject.keyword | Republic of Korea | - |
dc.contributor.alternativeName | Park, Jung Won | - |
dc.contributor.affiliatedAuthor | 박중원 | - |
dc.citation.volume | 36 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1001 | - |
dc.citation.endPage | 1013 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, Vol.36(4) : 1001-1013, 2021-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.